Antidepressants in pregnancy: a systematic review

References

• Johnson GL. Birth outcomes in pregnant women taking fluoxetine. J Fam Pract 1997; 44:32.
   Google Scholar
• Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, . Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295:499–507.
   PubMed Web of Science ®Google Scholar
• Shadigian E, Bauer ST. Pregnancy-associated death: a qualitative systematic review of homicide and suicide. Obstet Gynecol Surv 2005; 60:183–90.
   PubMed Web of Science ®Google Scholar
• Oates M. Suicide: the leading cause of maternal death. Br J Psychiatry 2003; 183:279–81.
   PubMed Web of Science ®Google Scholar
• Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49:726–35.
   PubMed Web of Science ®Google Scholar
• Alder J, Fink N, Bitzer J, Hosli I, Holgreve W. Depression and anxiety during pregnancy: A risk factor for obstetric, fetal and neonatal outcome? A review of the literature. J Maternal Fetal Neonatal Medicine 2007; 20:189–209.
   PubMed Web of Science ®Google Scholar
• Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95:487–90.
   PubMed Web of Science ®Google Scholar
• Austin MP, Leader L. Maternal stress and obstetric and infant outcomes: epidemiological findings and neuroendocrine mechanisms. Aust N Z J Obstet Gynaecol 2000; 40:331–7.
   PubMed Web of Science ®Google Scholar
• Murray L, Cooper P. Postpartum depression and child development. Psychol Med 1997; 27:253–60.
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65:230–7.
   PubMed Web of Science ®Google Scholar
• Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003; 160:993–6.
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72:184–91.
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73:330–7.
   PubMed Web of Science ®Google Scholar
• Loughhead AM, Fisher AD, Newport DJ, Ritchie JC, Owens MJ, DeVane CL, . Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry 2006; 163:145–7.
   PubMed Web of Science ®Google Scholar
• Loughhead AM, Stowe ZN, Newport DJ, Ritchie JC, DeVane CL, Owens MJ. Placental passage of tricyclic antidepressants. Biol Psychiatry 2006; 59:287–90.
   PubMed Web of Science ®Google Scholar
• O'Brien L, Einarson TR, Sarkar M, Einarson A, Koren G. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 2008; 30:696–701.
   PubMedGoogle Scholar
• Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol 2006; 22:571–5.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005; 14:823–7.
   PubMed Web of Science ®Google Scholar
• Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, . Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007; 29:918–26.
   PubMed Web of Science ®Google Scholar
• Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010–5.
   PubMed Web of Science ®Google Scholar
• Diav-Citrin OSS, Weinbaum D, Wajnberg R, Avgil M, Gianantonio E, Clementi C, Weber-Schoendorfer C, Schaefer C and Ornoy A. Paroxetine and Fluoxetine in pregnancy: a prospective, multicentre, controlled observational study. British journal of Clinical Pharmacology 2008; 66:695–705.
   PubMed Web of Science ®Google Scholar
• Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, . Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269:2246–8.
   PubMed Web of Science ®Google Scholar
• Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology 1996; 53:304–8.
   Google Scholar
• Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, . Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279:609–10.
   PubMed Web of Science ®Google Scholar
• Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, . Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158:1728–30.
   PubMed Web of Science ®Google Scholar
• Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, . A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003; 48:106–10.
   PubMed Web of Science ®Google Scholar
• Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, . Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192:932–6.
   PubMed Web of Science ®Google Scholar
• Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2005; 193:2004–9.
   PubMed Web of Science ®Google Scholar
• Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav-Citrin O, . Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006; 67:1280–4.
   PubMed Web of Science ®Google Scholar
• Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, . Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165:749–52.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89(5 Pt 1):713–8.
   Google Scholar
• Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, . Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142:402–8.
   PubMed Web of Science ®Google Scholar
• Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188:812–5.
   PubMed Web of Science ®Google Scholar
• Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, . Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557–66.
   PubMed Web of Science ®Google Scholar
• Kallen BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17:255–61.
   PubMed Web of Science ®Google Scholar
• Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79:301–8.
   PubMed Web of Science ®Google Scholar
• Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55:503–8.
   PubMed Web of Science ®Google Scholar
• Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106:1289–96.
   PubMed Web of Science ®Google Scholar
• Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007; 27:607–13.
   PubMed Web of Science ®Google Scholar
• Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, . Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17:701–4.
   PubMed Web of Science ®Google Scholar
• Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1075–85.
   PubMed Web of Science ®Google Scholar
• Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, . Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007; 16:1086–94.
   PubMed Web of Science ®Google Scholar
• Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159:2055–61.
   PubMed Web of Science ®Google Scholar
• Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, . Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194:961–6.
   PubMed Web of Science ®Google Scholar
• Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH, Jr., Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84:23–7.
   PubMed Web of Science ®Google Scholar
• Rosa F. Medicaid antidepressant pregnancy exposure outcomes. Reproductive Toxicology [Abstract]. 1994; 8:444–5.
   Google Scholar
• Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80:18–27.
   PubMed Web of Science ®Google Scholar
• Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356:2684–92.
   PubMed Web of Science ®Google Scholar
• Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356:2675–83.
   PubMed Web of Science ®Google Scholar
• Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008; 192:344–50.
   PubMed Web of Science ®Google Scholar
• Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005; 39:803–9.
   PubMed Web of Science ®Google Scholar
• Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Jr., Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005; 25:595–604.
   PubMedGoogle Scholar
• Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158:312–6.
   PubMed Web of Science ®Google Scholar
• Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156:1129–32.
   PubMed Web of Science ®Google Scholar
• Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113:368–75.
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63:898–906.
   PubMed Web of Science ®Google Scholar
• Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007; 164:1206–13.
   PubMed Web of Science ®Google Scholar
• Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008; 115:283–9.
   PubMed Web of Science ®Google Scholar
• Pearson KH, Nonacs RM, Viguera AC, Heller VL, Petrillo LF, Brandes M, . Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 2007; 68:1284–9.
   PubMedGoogle Scholar
• Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, . Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336:258–62.
   PubMed Web of Science ®Google Scholar
• Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48:996–1000.
   PubMed Web of Science ®Google Scholar
• Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, . Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159:1889–95.
   PubMed Web of Science ®Google Scholar
• Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004; 26:685–7.
   PubMed Web of Science ®Google Scholar
• Suri R, Altshuler L, Hendrick V, Rasgon N, Lee E, Mintz J. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004; 7:193–200.
   PubMedGoogle Scholar
• Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008; 192:338–43.
   PubMed Web of Science ®Google Scholar
• Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60:720–6.
   PubMed Web of Science ®Google Scholar
• Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez-Diaz S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009; 29:555–60.
   PubMed Web of Science ®Google Scholar
• Ferreira E, Carceller AM, Agogue C, Martin BZ, St-Andre M, Francoeur D, . Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119:52–9.
   PubMed Web of Science ®Google Scholar
• Eggermont E, Raveschot J, Deneve V, Casteels-van Daele M. The adverse influence of imipramine on the adaptation of the newborn infant to extrauterine life. Acta Paediatr Belg 1972; 26:197–204.
   PubMedGoogle Scholar
• Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J (Clin Res Ed) 1982; 284:1837–8.
   PubMed Web of Science ®Google Scholar
• Ostergaard GZ, Pedersen SE. Neonatal effects of maternal clomipramine treatment. Pediatrics 1982; 69:233–4.
   PubMed Web of Science ®Google Scholar
• Eggermont E. Withdrawal symptoms in neonates associated with maternal imipramine therapy. Lancet 1973; 2:680.
   Web of Science ®Google Scholar
• Idanpaan-Heikkila J, Saxen L. Possible teratogenicity of imipramine-chloropyramine. Lancet 1973 Aug 11; 2:282–4.
   PubMed Web of Science ®Google Scholar
• Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21:157–71.
   PubMed Web of Science ®Google Scholar
• Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160:173–6.
   PubMed Web of Science ®Google Scholar
• Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol 2008; 28:334–9.
   PubMed Web of Science ®Google Scholar
• Schwarzer V, Heep A, Gembruch U, Rohde A. Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine. Arch Gynecol Obstet 2008; 277:67–9.
   PubMed Web of Science ®Google Scholar
• Sokolover N, Merlob P, Klinger G. Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. Can J Clin Pharmacol 2008; 15:e188–90.
   Google Scholar
• Eyal R, Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry 2008; 165:651.
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, . Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579–87.
   PubMed Web of Science ®Google Scholar
• Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17:801–6.
   PubMed Web of Science ®Google Scholar
• Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, . Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009; 18:246–52.
   PubMed Web of Science ®Google Scholar
• Mattson SN, Eastvold AD, Jones KL, Harris JA, Chambers CD. Neurobehavioural follow-up of children prenatally exposed to fluoxetine. Teratology [Abstract]. 1999; 59:376.
   Google Scholar
• Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE, . Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006; 163:1026–32.
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007; 161:22–9.
   PubMed Web of Science ®Google Scholar
• Norquay C. Therapeutic Guidelines: Psychotropics Version 6. West Melbourne, Victoria: Therapeutic Guidelines Limited; 2008.
   Google Scholar
• National Institute of Health and Clinical Excellence: Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance Clinical Guideline CG45. 2007 [cited 18 March 2010] Available from URL: http://guidance.nice.org.uk/CG45
   Google Scholar
• Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, . The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009; 114:703–13.
   PubMed Web of Science ®Google Scholar
• Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2009.
   Google Scholar